Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript

Oct 30, 2025 / 12:00 PM GMT

Release Date Price: €36.2 (-2.69%)

Transcript 10-Q8-K

Key Points

Positve

Agios Pharmaceuticals Inc (AGIO) reported a 44% increase in net revenue for Q3 2025 compared to the same period in 2024, highlighting strong commercial execution.
The company has a robust balance sheet with approximately $1.3 billion in cash and investments, enabling strategic investments in future growth.
Agios Pharmaceuticals Inc (AGIO) received its first global regulatory approval for pyrokine in adults with thalassemia in Saudi Arabia, marking a significant milestone.
The company completed enrollment in the phase 2B trial of Teva Pivot for lower risk myelodysplastic syndromes, with top-line data expected early next year.
Agios Pharmaceuticals Inc (AGIO) is well-positioned for potential US launches of pyrokine for thalassemia and sickle cell disease, supported by a strong commercial model and partnerships.

Negative

The FDA's request for a REMS program has delayed the PDUFA date for pyrokine thalassemia supplemental NDA to December 7th, potentially impacting the launch timeline.
R&D expenses increased by $14.3 million compared to the third quarter of 2024, primarily due to higher clinical trial costs, which could pressure margins.
The company faces challenges in securing national procurement agreements in Saudi Arabia, which could delay broader market access and revenue realization.
The pricing and reimbursement process in Europe could take 12 to 18 months post-approval, delaying commercial opportunities in the region.
Agios Pharmaceuticals Inc (AGIO) is navigating potential safety concerns related to hepatocellular injury risk in thalassemia, which may impact physician prescribing behavior.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AGIO.OQ - Agios Pharmaceuticals Inc
Q3 2025 Agios Pharmaceuticals Inc Earnings Call
Oct 30, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Agios Pharmaceuticals Third quarter 2025 conference call. At this time, all participants are on a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Audio's request. I would now like to turn the call over to Morgan Sanford, head of industrial relations at Audio. Please go ahead, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good morning, everyone.

Thank you for joining us to discuss Audios Pharmaceuticals 3rd quarter 2025

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.